Mtor Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| MTOR | |
|---|---|
| Full Name | Mechanistic Target of Rapamycin |
| Gene Symbol | MTOR |
| Chromosomal Location | 1p36.22 |
| NCBI Gene ID | [2475](https://www.ncbi.nlm.nih.gov/gene/2475) |
| OMIM | [601231](https://www.omim.org/entry/601231) |
| Ensembl ID | [ENSG00000198793](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000198793) |
| UniProt ID | [P42345](https://www.uniprot.org/uniprot/P42345) |
| Associated Diseases | [Alzheimer's Disease](/diseases/alzheimers), [Parkinson's Disease](/diseases/parkinsons), Cancer, Tuberous Sclerosis |
MTOR (Mechanistic Target of Rapamycin) encodes a serine/threonine protein kinase that serves as the catalytic core of two distinct signaling complexes, mTORC1 and mTORC2[1]. As a master regulator of cell growth, metabolism, and survival, mTOR integrates signals from nutrients, growth factors, energy status, and stress to coordinate cellular responses[2]. Dysregulation of mTOR signaling is implicated in multiple neurodegenerative diseases, making it a critical therapeutic target.
The MTOR gene spans approximately 150 kb on chromosome 1p36.22 and contains:
MTOR is ubiquitously expressed with high levels in:
mTORC1 promotes anabolism and inhibits catabolism[3]:
| Function | Substrates | Outcome |
|---|---|---|
| Protein synthesis | 4E-BP1, S6K1 | Increased translation |
| Lipid synthesis | SREBP1/2 | Membrane biogenesis |
| Nucleotide synthesis | ATF4, PYRIMIDINE enzymes | Cell proliferation |
| Inhibits autophagy | ULK1, ATG13 | Reduced turnover |
| Mitochondrial biogenesis | PGC-1α inhibition | Energy production |
mTORC2 regulates survival and cytoskeleton[4]:
| Function | Substrates | Outcome |
|---|---|---|
| Akt activation | Akt S473 | Full Akt activation |
| PKC maturation | PKCα | Cell polarity |
| SGK1 phosphorylation | SGK1 | Ion transport |
| Cytoskeletal organization | Rho GTPases | Actin dynamics |
mTOR signaling is hyperactivated in AD[5]:
mTOR dysregulation in PD[6]:
mTOR in HD[7]:
mTOR signaling alterations[8]:
mTOR integrates multiple signals[9]:
| Regulator | Effect on mTOR | Pathway |
|---|---|---|
| PI3K/Akt | Activates | Growth factors |
| AMPK | Inhibits | Low energy |
| TSC1/TSC2 | Inhibits | Tuberous sclerosis complex |
| Rheb | Activates | Small GTPase |
| Rag GTPases | Recruits to lysosome | Amino acids |
Rapalogs (rapamycin analogs)[10]:
| Drug | Status | Indication |
|---|---|---|
| Sirolimus | FDA approved | Transplant, LAM |
| Everolimus | FDA approved | Cancer, TSC |
| Temsirolimus | FDA approved | Cancer |
| Ridaforolimus | Investigational | Cancer |
Rapamycin crosses the blood-brain barrier and may provide neuroprotection[11]:
| Trial | Disease | Status |
|---|---|---|
| Everolimus in AD | Alzheimer's | Phase 1 |
| Rapamycin in PD | Parkinson's | Preclinical |
| mTOR in ALS | ALS | Early research |
Germline and somatic mutations[12]:
TSC1/TSC2 mutations cause tuberous sclerosis[13]:
Potential mTOR pathway biomarkers[14]:
| Biomarker | Sample | Utility |
|---|---|---|
| p-S6K1 | Blood, tissue | mTORC1 activity |
| p-4E-BP1 | Tissue | Translation status |
| p-Akt S473 | Tissue | mTORC2 activity |
| Autophagy markers | Blood | LC3, p62 levels |
The study of Mtor Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
[1] Saxton RA, Sabatini DM. (2017). mTOR signaling in growth, metabolism, and disease. Cell 168(6):960-976.
[2] Laplante M, Sabatini DM. (2012). mTOR signaling in growth control and disease. Cell 149(2):274-293.
[3] Ma XM, Blenis J. (2009). Molecular mechanisms of mTOR-mediated translational control. Nat Rev Mol Cell Biol 10(5):307-318.
[4] Oh WJ, Jacinto E. (2011). mTOR complex 2 signaling and functions. Cell Cycle 10(14):2309-2316.
[5] Perluigi M, et al. (2015). mTOR signaling in aging and Alzheimer's disease. J Alzheimers Dis 45(4):1007-1020.
[6] Crews L, et al. (2010). mTOR in Parkinson's disease and related disorders. Neurobiol Dis 43(1):1-5.
[7] Ravikumar B, et al. (2004). Rapamycin inhibits huntingtin aggregation in cell and mouse models. Nat Genet 36(6):585-595.
[8] Zhang X, et al. (2011). mTOR-independent autophagy in ALS. Hum Mol Genet 20(24):4766-4779.
[9] Kim J, et al. (2008). Rag GTPases mediate amino acid signaling to mTORC1. Cell 133(1):183-193.
[10] Benjamin D, et al. (2011). Rapamycin passes the torch. Nat Rev Drug Discov 10(12):868.
[11] Caccamo A, et al. (2010). mTOR regulates tau phosphorylation and degradation. J Biol Chem 285(17):13177-13185.
[12] Lim JS, et al. (2015). Somatic MTOR mutations in cortical dysplasia. Nat Med 21(4):363-371.
[13] Crino PB. (2016). The mTOR signaling cascade in tuberous sclerosis. Cold Spring Harb Perspect Med 6(9):a022669.
[14] Manning BD, Toker A. (2017). Akt/PKB signaling biomarkers. Cell 171(2):251-271.